Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2 clinical trials
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Combination Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

This phase III trial aims to compare the progression free survival (PFS) and safety of fulvestrant or capecitabine as maintenance therapy after first-line combined chemotherapy in hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer.

erbb2
liver metastasis
epidermal growth factor receptor
immunohistochemistry
epidermal growth factor
  • 0 views
  • 19 Feb, 2024
PAXG Out in the Country

The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

pdac
pancreatic adenocarcinoma
metastasis
cisplatin
pancreatic ductal adenocarcinoma
  • 0 views
  • 19 Feb, 2024